Cadila Healthcare Ltd (Zydus Cadila), on Tuesday, said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.

It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04, the company said here.